Publicaciones
Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer’s disease: A randomized, double-blind, placebo-controlled phase 2 study.
María Pascual-Lucas, et al. Alzheimer’s & Dementia 2025
AB1601 phase 2 study of ABvac40, an anti-Aβ40 vaccine: safety and immunogenicity of a cross-over extension
Poster presentation AAIC 2023. María Pascual-Lucas, et al.
ABvac40 induces anti-Aβx-40 plasma specific antibodies that bind with Aβ vascular deposits in brain slices from humans with cerebral amyloid angiopathy.
Montañés M, Canudas J, Martínez I, et al. CTAD 2023, poster presentation
Update phase 2 study of ABvac40, an active vaccine anti-aβ40 in patients with mild cognitive impairment or very-mild Alzheimer’s disease
Molina E, Castillo S, Lacosta AM, et al. AD/PD 2022, poster presentation
ABvac40 elicits a predominantly Th2 immune response that supports its excellent safety profile
Poster presentation CTAD 2022—ABVac40 Safety profile information Montañes M, Martín C, Castillo S et al.
A multi-center, randomized, double blind, placebo-controlled Phase 2 study in patients with aMCI or very mild AD to investigate the safety, tolerability and immune response of ABvac40.
Molina E, Pesini P, Sarasa-San Jose M, et al. AAIC 2020, poster presentation.
Safety, tolerability and immunogenicity of an active anti-Abeta40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial
Lacosta AM, Pascual-Lucas M, Pesini P, et al. Alzheimers Res Ther. 2018; 10:12.
Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer’s disease in individuals with subjective cognitive decline: 5-year follow-up of the FACEHBI cohort
Noelia Fandos, et al. The Journal of Prevention of Alzheimer's Disease 2026
Clinical validation of a plasma-based antibody-free LC–MS method for identifying CSF amyloid positivity in mild cognitive impairment.
Jose Antonio Allué, et al. Frontiers in Aging Neuroscience 2025
Clinical utility of an antibody-free LC-MSmethod to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study
Jose Antonio Allué, et al. Alzheimer’s Dementia Diagnosis Assessment Disease Monitoring 2023
Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity
Chun Ming Young, et al. Frontiers in Anging Neuroscience 2023.
Association of plasma Aβ42/Aβ40 with episodic memory performance and brain atrophy in individuals at risk of Alzheimer’s disease
Poster presentation ADPD 2023. María Pascual-Lucas, et al.
Clinical performance of an antibody free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
Pascual-Lucas M, Allué JA, Sarasa L et al. Alzheimer’s Research & Therapy 2023; 15:2
Comparative performance of plasma Aβ42/Aβ40 and p‐tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline.
Poster presentation CTAD 2022—ABtest MS FACEHBI Cohort Pascual-Lucas M, Allué JA, Sarasa L et al.
Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S, Palmqvist S, Leuzy A et al. Alzheimer’s Dement 2022; 18:283-293
Plasma Aβ42/Aβ40, measured by a novel mass spectrometric method, identifies early amyloid deposition in individuals at risk of Alzheimer’s disease (FACEHBI Cohort)
Oral Presentation ADPD 2022 – AbtestMS_FACEHBI Allué JA, Sarasa L, Pascual-Lucas M
Accurate discrimination of brain amyloid status in the multi-centric A4 study by plasma Aβ42/Aβ40 measured with a novel hplc-ms/ms method
Sarasa L, Pascual - Lucas M, Allué JA, et al. AD/PD 2022. poster presentation.
The global Alzheimer’s Association round robin study on plasma amyloid β methods
Pannee J, Shaw LM, Korecka M at al. Alzheimers Dement 2021; 14;13(1):e12242
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
Cullen N, Leuzy A, Palmqvist S et al. Nature Aging 2021; 1:114–123
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort
Jang H, Kim Js, Lee HJ et al. Alz Res Therapy 2021; 13:179
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
Janelidze S, Teunissen CE, Zetterberg H et al. JAMA Neurol. 2021;78:1375-1382.
Aβ42/Aβ40 ratio in plasma predicts amyloid‐PET status in
Pascual‐Lucas M, Sarasa L, Molina E, et al. AAIC 2021, poster presentation.
Antibody free, Mass Spectrometric procedure for the determination of Aβ40 and Aβ42 in human plasma.
Allué JA, Sarasa L, Castillo S, et al. CTAD 2020, poster presentation.
ABtest-IA: A new reliable tool for the quantification of Aβ40 and Aβ42 in CSF
Poster presentation AAIC 2022—ABtest IA CSF Validation Fandos N, Romero J, Pascual-Lucas M, et al. AAIC 2022, poster presentation.
Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.
Verberk IMW, Misdorp E, Koelewijn J et al. Alzheimers Dement 2022; 18:1484-1497.
The global Alzheimer’s Association round robin study on plasma amyloid β methods
Pannee J, Shaw LM, Korecka M at al. Alzheimers Dement 2021; 14;13(1):e12242
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
Burnham SC, Fandos N, Fowler C, et al. Brain Communications. 2020; 2, 1-7.
Total Abeta42/Abeta40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke JD, Pérez-Grijalba V, Fandos N, et al. Neurology. 2020; 94: e1580-e1591.
Plasma Abeta42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study
Pérez-Grijalba V, Romero J, Pesini P, et al. J Prev Alzheimers Dis. 2019-b; 6:34-41.
Plasma Abeta42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
Pérez-Grijalba V, Arbizu J, Romero J, et al. Alzheimers Res Ther. 2019; 11:96.
Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
Risacher SL, Fandos N, Romero J, et al. Alzheimers Dement (Amst). 2019; 11:510-519.
Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)
De Rojas I, Romero J, Rodríguez-Gómez O, et al. Alzheimers Res Ther. 2018; 10:119.
Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals.
Fandos N, Pérez-Grijalba V, Pesini P, et al. Alzheimers Dement (Amst). 2017; 8:179-187.
Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Abeta40 and Abeta42 Peptides in Plasma.
Pérez-Grijalba V, Fandos N, Canudas J, et al. J Alzheimers Dis. 2016; 54:751-62.